Financial Performance - Net loss for Q3 2024 was $18.4 million, a decrease of 41.4% compared to $31.4 million in Q3 2023[2] - Net loss for the nine months ended September 30, 2024, was $76.6 million, a reduction of 10.3% from $85.9 million for the same period in 2023[6] Research and Development Expenses - Research and development expenses for Q3 2024 were $13.3 million, down 50.7% from $27.0 million in Q3 2023[3] - Research and development expenses for the nine months ended September 30, 2024, totaled $60.8 million, down 18.1% from $74.2 million in the same period of 2023[7] General and Administrative Expenses - General and administrative expenses for Q3 2024 were $6.4 million, a slight decrease of 7.2% compared to $6.9 million in Q3 2023[4] - General and administrative expenses for the nine months ended September 30, 2024, increased to $20.9 million, up 6.7% from $19.6 million in the same period of 2023[8] Operating Expenses - Total operating expenses for Q3 2024 were $19.8 million, a decrease of 41.7% from $33.9 million in Q3 2023[11] Workforce Reduction - The company reduced its workforce by approximately 40%, affecting 47 employees, incurring $0.9 million in restructuring charges[5] Cash and Assets - As of September 30, 2024, the company had cash and cash equivalents and marketable securities totaling $97.9 million[8] - Total assets as of September 30, 2024, were $108.5 million, down from $173.3 million as of December 31, 2023[12]

How to Determine if a Stock is Oversold quest for reaching the old equilibrium of supply and demand. Rapt Therapeutics (RAPT) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. We use Relative Strength Index (RSI), one of th ...

Rapt Therapeutics (RAPT) has been beaten down lately with too much selling pressure. While the stock has lost 47.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillato ...

Shidlovski/iStock via Getty Images Thesis overview RAPT Therapeutics (NASDAQ:RAPT) is developing oral small molecule therapies for inflammation (atopic dermatitis and asthma) and oncology indications. The most advanced candidate is zelnecirnon (ZEL) currently in ph2 stage for the indications of atopic dermatitis (AD) and asthma, with promising phase 1 safety and efficacy results in AD. RAPT was trading at a market cap close to $900M up until recently, when RAPT announced an FDA clinical hold due to hepatic ...

Rapt Therapeutics (RAPT) has been beaten down lately with too much selling pressure. While the stock has lost 52.9% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscilla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | --- | --- | | Title of each class | S ...

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif. – May 9, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 202 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-3313701 (State or other jurisdiction of incorp ...

"We are working diligently to lift the clinical hold on our Phase 2 trials of zelnecirnon in atopic dermatitis and asthma," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "Patient safety is our top priority. We expect to provide an update once we have defined a plan to move ahead and appreciate your patience during this process. Separately, our Phase 2 study of tivumecirnon in cancer is ongoing and we will be presenting an update at AACR in April." Financial Result ...

For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 RAPT Therapeutics, Inc. For the transition period from to | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of each exchange on which registered | | Common St ...